Prenatal factors associated with the development of eczema in the first year of life

Margaret Kurzius-Spencer, Marilyn Halonen, I. Carla Lohman, Fernando Martinez, Anne L Wright

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Prenatal factors have been implicated in childhood eczema, but the relationship between maternal cytokine production during pregnancy and infant eczema is unknown. Non-selected women in their third trimester were enrolled in the Tucson Infant Immune Study. Data from three sources were used to define MD-eczema: parent-completed illness questionnaires at age 2, 3, 4, 6 and 9 months regarding physician-seen eczema, parent-completed questionnaires at 12 months regarding physician-diagnosed eczema, and medical record reviews. Blood samples were taken from mothers during their third trimester and from the umbilical cord at birth. Maternal peripheral blood mononuclear cells and cord blood mononuclear cells were stimulated with ConA/PMA, and supernatants were assayed for IFN-γ and IL-4, -5, -10, and -13. Of 364 children, 28% were seen by a physician for eczema by 1 yr of age. After adjustment for potential confounders using logistic regression, the odds for development of eczema in infancy were significantly higher when mothers had active eczema in pregnancy (OR, 2.46, CI 1.0-5.8, p < 0.042) and when mothers were in the highest tertile of serum IgE production (OR 2.28, CI 1.2-4.4, p < 0.013). Colds in the third trimester were associated with lower odds of eczema (OR 0.32, CI 0.16-0.63, p < 0.001). Our findings from this cohort study suggest that in utero factors, including maternal IgE, colds, and eczema, may influence the risk of infant eczema.

Original languageEnglish (US)
Pages (from-to)19-26
Number of pages8
JournalPediatric Allergy and Immunology
Volume16
Issue number1
DOIs
StatePublished - Feb 2005

Fingerprint

Eczema
Mothers
Third Pregnancy Trimester
Physicians
Immunoglobulin E
Blood Cells
Pregnancy
Umbilical Cord
Information Storage and Retrieval
Interleukin-5
Fetal Blood
Interleukin-4
Medical Records
Cohort Studies
Logistic Models
Parturition
Cytokines

Keywords

  • Atopic dermatitis
  • IgE
  • IL-10
  • Infantile eczema
  • Maternal asthma
  • Maternal-fetal exchange

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pediatrics, Perinatology, and Child Health
  • Immunology

Cite this

Prenatal factors associated with the development of eczema in the first year of life. / Kurzius-Spencer, Margaret; Halonen, Marilyn; Lohman, I. Carla; Martinez, Fernando; Wright, Anne L.

In: Pediatric Allergy and Immunology, Vol. 16, No. 1, 02.2005, p. 19-26.

Research output: Contribution to journalArticle

@article{f7a4fb2ebf3a4e41bac70db5a7395941,
title = "Prenatal factors associated with the development of eczema in the first year of life",
abstract = "Prenatal factors have been implicated in childhood eczema, but the relationship between maternal cytokine production during pregnancy and infant eczema is unknown. Non-selected women in their third trimester were enrolled in the Tucson Infant Immune Study. Data from three sources were used to define MD-eczema: parent-completed illness questionnaires at age 2, 3, 4, 6 and 9 months regarding physician-seen eczema, parent-completed questionnaires at 12 months regarding physician-diagnosed eczema, and medical record reviews. Blood samples were taken from mothers during their third trimester and from the umbilical cord at birth. Maternal peripheral blood mononuclear cells and cord blood mononuclear cells were stimulated with ConA/PMA, and supernatants were assayed for IFN-γ and IL-4, -5, -10, and -13. Of 364 children, 28{\%} were seen by a physician for eczema by 1 yr of age. After adjustment for potential confounders using logistic regression, the odds for development of eczema in infancy were significantly higher when mothers had active eczema in pregnancy (OR, 2.46, CI 1.0-5.8, p < 0.042) and when mothers were in the highest tertile of serum IgE production (OR 2.28, CI 1.2-4.4, p < 0.013). Colds in the third trimester were associated with lower odds of eczema (OR 0.32, CI 0.16-0.63, p < 0.001). Our findings from this cohort study suggest that in utero factors, including maternal IgE, colds, and eczema, may influence the risk of infant eczema.",
keywords = "Atopic dermatitis, IgE, IL-10, Infantile eczema, Maternal asthma, Maternal-fetal exchange",
author = "Margaret Kurzius-Spencer and Marilyn Halonen and Lohman, {I. Carla} and Fernando Martinez and Wright, {Anne L}",
year = "2005",
month = "2",
doi = "10.1111/j.1399-3038.2005.00233.x",
language = "English (US)",
volume = "16",
pages = "19--26",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "1",

}

TY - JOUR

T1 - Prenatal factors associated with the development of eczema in the first year of life

AU - Kurzius-Spencer, Margaret

AU - Halonen, Marilyn

AU - Lohman, I. Carla

AU - Martinez, Fernando

AU - Wright, Anne L

PY - 2005/2

Y1 - 2005/2

N2 - Prenatal factors have been implicated in childhood eczema, but the relationship between maternal cytokine production during pregnancy and infant eczema is unknown. Non-selected women in their third trimester were enrolled in the Tucson Infant Immune Study. Data from three sources were used to define MD-eczema: parent-completed illness questionnaires at age 2, 3, 4, 6 and 9 months regarding physician-seen eczema, parent-completed questionnaires at 12 months regarding physician-diagnosed eczema, and medical record reviews. Blood samples were taken from mothers during their third trimester and from the umbilical cord at birth. Maternal peripheral blood mononuclear cells and cord blood mononuclear cells were stimulated with ConA/PMA, and supernatants were assayed for IFN-γ and IL-4, -5, -10, and -13. Of 364 children, 28% were seen by a physician for eczema by 1 yr of age. After adjustment for potential confounders using logistic regression, the odds for development of eczema in infancy were significantly higher when mothers had active eczema in pregnancy (OR, 2.46, CI 1.0-5.8, p < 0.042) and when mothers were in the highest tertile of serum IgE production (OR 2.28, CI 1.2-4.4, p < 0.013). Colds in the third trimester were associated with lower odds of eczema (OR 0.32, CI 0.16-0.63, p < 0.001). Our findings from this cohort study suggest that in utero factors, including maternal IgE, colds, and eczema, may influence the risk of infant eczema.

AB - Prenatal factors have been implicated in childhood eczema, but the relationship between maternal cytokine production during pregnancy and infant eczema is unknown. Non-selected women in their third trimester were enrolled in the Tucson Infant Immune Study. Data from three sources were used to define MD-eczema: parent-completed illness questionnaires at age 2, 3, 4, 6 and 9 months regarding physician-seen eczema, parent-completed questionnaires at 12 months regarding physician-diagnosed eczema, and medical record reviews. Blood samples were taken from mothers during their third trimester and from the umbilical cord at birth. Maternal peripheral blood mononuclear cells and cord blood mononuclear cells were stimulated with ConA/PMA, and supernatants were assayed for IFN-γ and IL-4, -5, -10, and -13. Of 364 children, 28% were seen by a physician for eczema by 1 yr of age. After adjustment for potential confounders using logistic regression, the odds for development of eczema in infancy were significantly higher when mothers had active eczema in pregnancy (OR, 2.46, CI 1.0-5.8, p < 0.042) and when mothers were in the highest tertile of serum IgE production (OR 2.28, CI 1.2-4.4, p < 0.013). Colds in the third trimester were associated with lower odds of eczema (OR 0.32, CI 0.16-0.63, p < 0.001). Our findings from this cohort study suggest that in utero factors, including maternal IgE, colds, and eczema, may influence the risk of infant eczema.

KW - Atopic dermatitis

KW - IgE

KW - IL-10

KW - Infantile eczema

KW - Maternal asthma

KW - Maternal-fetal exchange

UR - http://www.scopus.com/inward/record.url?scp=14644392150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644392150&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3038.2005.00233.x

DO - 10.1111/j.1399-3038.2005.00233.x

M3 - Article

VL - 16

SP - 19

EP - 26

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 1

ER -